Bausch & Lomb Corp (BLCO)

Bausch & Lomb has been a fixture in vision care for more than 170 years, evolving from a single optical-goods retailer into a diversified pharmaceutical and medical-device company focused on eye health. The company develops and manufactures medications for ocular diseases, contact-lens solutions, intraocular lenses for cataract surgery, and consumer vision-care products, serving patients, ophthalmologists, and retailers across the world.

From optical retailer to global eye-health enterprise

Bausch & Lomb was founded in 1853 by John Jacob Bausch and Henry Lomb, German immigrant opticians who set up shop in Rochester, New York. The company initially made and sold eyeglasses and optical instruments—spectacle lenses, frames, and the equipment to grind lenses. For the first century of its existence, Bausch & Lomb was essentially a supplier to optometrists and optical retailers, making the tools and materials of the eye-care trade.

The company’s first significant product diversification came with the development of contact lenses. By the mid-20th century, Bausch & Lomb had become a dominant supplier of contact lenses, an invention that promised wearers a more natural visual experience and a cosmetic advantage over eyeglasses. Contact-lens solutions and care products naturally followed. Through this period, Bausch & Lomb positioned itself closer to the end consumer, not just to professionals.

The turning point came in 1981 when Bausch & Lomb introduced Soflens contact lenses, a soft silicone hydrogel design that was more comfortable and durable than previous materials. The success of Soflens cemented the company’s position in a lucrative market and drove substantial profit growth. By the 1990s, Bausch & Lomb began acquiring complementary eye-health companies and expanding into pharmaceuticals—drugs to treat dry eye, glaucoma, and other ocular conditions.

The transformation to pharmaceutical and medical-device focus

Throughout the 1990s and 2000s, Bausch & Lomb shifted its strategic center from consumer contact-lens products toward higher-margin pharmaceuticals and surgical devices. The company made acquisitions in each domain: surgical devices for cataract removal and lens implantation, dry-eye medications, and treatments for age-related macular degeneration (AMD). This transformation was gradual but steady, reflecting the industry trend toward treating eye disease as a pharmaceutical problem rather than a vision-correction problem.

In 2013, the Valeant Pharmaceutical Group (later renamed Bausch Health Companies) acquired Bausch & Lomb in a major consolidation. For a decade, Bausch & Lomb operated as a subsidiary within a larger conglomerate. During this period, the company continued to develop new medications and acquire smaller eye-care companies, building a portfolio in surgical devices, glaucoma treatments, and retinal health.

In May 2022, Bausch & Lomb was spun off as an independent publicly traded company, returning to the public markets after 30 years as a private subsidiary. The spin-off was designed to allow Bausch & Lomb to operate independently, pursue targeted acquisitions in eye health, and attract capital from investors focused specifically on ophthalmology.

Three pillars of the modern business

Pharmaceuticals represent the largest share of revenue and profit. Bausch & Lomb develops and commercializes medications for glaucoma (eye pressure reduction), dry eye disease, retinal disease, and corneal health. Many of these medications are sold globally through ophthalmologists and optometrists. Glaucoma drugs are particularly valuable because they are chronic treatments—patients take them for years or decades—creating recurring revenue. Dry eye disease has emerged as a major opportunity as aging populations and screen time have increased its prevalence.

Surgical devices and lenses are the second major segment. Intraocular lenses (IOLs) implanted during cataract surgery are high-margin products. Phacoemulsification machines (surgical equipment used to remove cataracts) and associated instruments round out the portfolio. These are sold to hospitals and surgical centers globally. The market is mature but large—cataract surgery is one of the most commonly performed surgical procedures in the world.

Consumer vision-care products include the Bausch & Lomb branded contact-lens solutions, rewetting drops, and other over-the-counter products sold through pharmacies and online retailers. While this segment is lower-margin than pharmaceuticals, it generates brand awareness and provides recurring revenue from retail sales. The consumer segment is relatively sensitive to competition and pricing pressure from private-label alternatives.

Business model and margins

Bausch & Lomb’s economics vary by segment. Pharmaceutical products carry high gross margins (often 70% or more) but require significant research, development, and regulatory approval costs upfront. Surgical devices also carry attractive margins but face competition and pricing pressure from global competitors like Johnson & Johnson (Alcon division) and Essilor-Luxottica. Consumer products have lower margins and higher distribution and marketing costs.

The company generates recurring revenue from chronic medications (glaucoma, dry eye) where patients refill prescriptions monthly or more frequently. It also benefits from the large and aging global population that requires cataract surgery and other eye treatments. However, it faces commodity-like pricing pressure in contact-lens solutions and competition from generic pharmaceuticals as patents expire.

Market position and competition

Bausch & Lomb is a significant but not dominant player in global eye health. It competes against much larger pharmaceutical companies (AbbVie, which owns Allergan, is a major dry-eye competitor) and specialized ophthalmology rivals (Alcon is a larger surgical-device player). The company’s strength lies in its integrated portfolio across pharmaceuticals, devices, and consumer products—allowing it to build long-term relationships with ophthalmologists and eye-care facilities.

The spin-off in 2022 was designed to unlock value by allowing the company to operate with a clearer strategic focus and the ability to make acquisitions without the constraints of a larger corporate parent. Early acquisitions have included additional eye-pharmaceuticals and surgical-device companies.

Key risks and opportunities

The principal risk is patent expiration on key medications. As patents expire, generic competitors enter and prices fall. The company must continue to develop new drugs to offset these losses. Regulatory changes—particularly in drug pricing in the United States and other major markets—could pressure profitability on blockbuster drugs.

The opportunity lies in the aging global population, rising incidence of eye diseases, and increasing access to eye care in emerging markets. Cataract surgery demand, for instance, is growing in India, China, and Southeast Asia as wealth rises. Bausch & Lomb is positioned to capture share of this growth.

How to research Bausch & Lomb as an investment

Bausch & Lomb’s annual 10-K (SEC CIK 0001860742) provides detailed segmentation by therapeutic area and geography and describes the competitive landscape in each domain. The company discloses patent expiration dates for key drugs and the R&D pipeline of candidates in development.

Earnings calls and guidance should be monitored for trends in each segment, pricing dynamics, and acquisition activity. Key metrics include revenue growth by segment, gross margin trends, operating profit, and cash generation. As with any pharmaceutical company, the pipeline of new drugs is critical—watch for regulatory approvals, clinical trial outcomes, and the runway of patent protection on key products. The company’s leverage and interest coverage matter because the spin-off involved significant debt, which must be managed as revenue and profitability evolve.